Search Results

You are looking at 171 - 180 of 211 items for :

  • "aggressiveness" x
  • Medical and Health Sciences x
  • All content x
Clear All

aggressive treatment of hypercholesterolemia. Circulation, 2008, 118 , 672–674. Witztum J. L. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia

Restricted access
Orvosi Hetilap
Authors: Zsófia Simon, Árpád Illés, Zsófia Miltényi, Ferenc Magyari, László Váróczy, Nikolett Péter, and Lajos Gergely

1664 Tadmor, T., McLaughlin, P., Polliack, A.: A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? Leuk. Lymphoma, 2010

Restricted access
Orvosi Hetilap
Authors: Ajándék Eőry, Xénia Gonda, Péter Torzsa, László Kalabay, and Zoltán Rihmer

Gonda, X., Fountoulakis, K. N., Csukly, G. és mtsai: Interaction of 5-HTTLPR genotype and unipolar major depression in the emergence of aggressive/hostile traits. J. Affect. Disord., 2011, 132 , 432–437. Csukly

Open access
Orvosi Hetilap
Authors: Balázs Tahin, Justin Cooke, Magdolna Grasselly, János László Iványi, Barna Szima, Mátyás Bobest, Erika Ligeti, Ferenc Brittig, Ferenc Garzuly, and Csaba Tóth

., Elwatidy, S., Elgamal, E.: Nocardia brain abscess: severe CNS infection that needs aggressive management; case report. Acta Neurochir. (Wien), 2008, 150 , 1097–1101. Elgamal E

Open access

factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am. J. Pathol., 2010, 176 , 1433–1442. Spruss T. Reduced expression of fibroblast growth factor

Open access

, Gloviczki P : Infected aortic aneurysms: Aggressive presentation, complicated early outcome, but durable results . J Vasc Surg 34 , 900 – 908 ( 2001 ) 10.1067/mva.2001.118084 2

Open access

–331. Khalifa, K. A., Badawy, H. M., Radwan, W. M., et al.: CD4 + HLA-DR low/ – monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma. Int. J. Lab. Hematol., 2014, 36 (6), 650–655. Nam, S. J

Restricted access

. S., Maron, D. J., et al.: Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden. Results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear

Restricted access

), 494–498. Mehta, M., Manon, R.: Are more aggressive therapies able to improve treatment of locally advanced non-small cell lung cancer: combined modality treatment? Semin. Oncol., 2005, 32 (2 Suppl. 3), S25–S34

Restricted access

al.: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation, 1996, 93 (10), 1826–1835. Spence, J. D

Restricted access